The downside is that nausea may be more noticeable during your work or daily activities, and you'll need to plan meals carefully to avoid overeating despite reduced hunger signals
Foremost, it is up to a doctor and their differential diagnoses based on your health history and pre-existing conditions, bloodwork, and body mass index
Regulatory agencies have weighed in
Specifically, NICE suggests considering a DPP-4 inhibitor as a second agent when: The patient has a high risk of hypoglycaemia (making sulfonylureas less suitable) Weight management is a concern and a sulfonylurea's weight-gaining effects are undesirable An SGLT-2 inhibitor is contraindicated or not tolerated NICE NG28 recommends that in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, an SGLT-2 inhibitor should generally be prioritised often alongside or instead of metformin due to its organ-protective benefits
It assesses pituitary gland health, aiding in the diagnosis of hormonal imbalances
It contains the same active ingredient found in Wegovy and Ozempic , helping regulate blood sugar levels and suppress appetite